2026-01-18 - Analysis Report
**1. Company Overview**
Regeneron Pharmaceuticals Inc is a biotechnology company.

**2. Return Comparison**

| Ticker | Cumulative Return |
| --- | --- |
| REGN | 25.37% |
| VOO | 93.36% |
| Divergence | -66.60 |
| Relative Divergence | 21.20% |

The divergence indicates that REGN's cumulative return is lower than VOO's cumulative return, and the current position is at the 21.20% percentile of past data.

**3. Alpha and Beta Analysis**

| Period | CAGR | MDD | Alpha | Beta | Cap (B)$ |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | -14.0% | 22.4% | -18.0% | 1.2 | 39.6 |
| 2017-2019 | -3.0% | 28.6% | -21.0% | 1.0 | 39.8 |
| 2018-2020 | 2.0% | 28.6% | -19.0% | 0.7 | 51.2 |
| 2019-2021 | 29.0% | 28.6% | -15.0% | 0.6 | 66.9 |
| 2020-2022 | 55.0% | 14.4% | 56.0% | 0.6 | 76.5 |
| 2021-2023 | 46.0% | 14.4% | 45.0% | 0.6 | 93.1 |
| 2022-2024 | -7.0% | 30.9% | -26.0% | 0.6 | 75.5 |
| 2023-2025 | -4.0% | 45.4% | -66.0% | 0.6 | 81.8 |

**4. Recent Stock Price Fluctuations**

* 5-day SMA: $751.20
* 20-day SMA: $772.91
* 60-day SMA: $721.13
* Close: $733.04
* Last-market: -$1.2%
* Recent fluctuation issue: The price has dropped by 1.2% recently.

**5. RSI and PPO Analysis**

* Market Risk Indicator (MRI): 0.80
* Risk Level: Medium
* Recent (20 days) relative divergence change: -8.60 (worsening)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.00 (flat)
* Expected Return: -44.70%
* RSI: 33.66
* PPO: -1.10

**6. Recent News & Significant Events**

* REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Yahoo Finance
* Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
* Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
* Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside - DirectorsTalk Interviews
* Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Analyst Buy Upgrades - simplywall.st
* REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Zacks Investment Research

**7. Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 826.04 / 1057.00 / 630.00

**8. Recent Earnings Analysis**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

**9. Financial Information**

### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

Overall Analysis:
REGN has shown a relatively lower cumulative return compared to VOO and has experienced a recent price drop. The company's alpha and beta analysis indicate varying performance across different periods. The MRI and risk level suggest a medium level of risk. The recent news and analyst opinions indicate a mixed view of the company's performance and potential. The earnings analysis shows consistent revenue and EPS growth. The financial information indicates a stable and profitable position. However, the expected return is currently low at -44.70%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.